title: Current Endoscopic Approaches for the Treatment of Barrett Esophagus.
abstract: Barrett esophagus (BE) is the only identifiable premalignant condition for esophageal adenocarcinoma (EAC), a cancer associated with a poor 5-year survival rate. The stepwise pathologic progression of BE to invasive cancer provides an opportunity to halt progression and potentially decrease incidence and ultimately the morbidity and mortality related to this lethal cancer. Endoscopic eradication therapy (EET) in patients at increased risk of progression to invasive EAC (intramucosal EAC, high-grade dysplasia, and low-grade dysplasia) is a practice that is endorsed by multiple societies and has replaced esophagectomy as the standard of care for these patients. Although the effectiveness, safety, and durability of EET have been demonstrated in several studies, this review addresses the several challenges with EET that need to be considered to optimize patient outcomes. Finally, the critical role of training, competence, and quality indicators in EET are emphasized in this era of value-based health care practice.
authors.affiliation: Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, CO.
authors.forename: Bryan
authors.initials: B
authors.lastname: Brimhall
authors.forename: Sachin
authors.initials: S
authors.lastname: Wani
mesh_terms: D000230:Adenocarcinoma / Q000209:etiology / Q000401:mortality / Q000601:surgery*; D001471:Barrett Esophagus / Q000150:complications / Q000601:surgery*; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000209:etiology / Q000401:mortality / Q000601:surgery*; D004945:Esophagoscopy / Q000379:methods* / Q000592:standards; D004947:Esophagus / Q000473:pathology / Q000601:surgery; D006801:Humans; D011230:Precancerous Conditions / Q000150:complications / Q000601:surgery*; D015996:Survival Rate; D016896:Treatment Outcome